Cretostimogene Grenadenorepvec
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Muscle Invasive Bladder Cancer
Conditions
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Trial Timeline
Dec 14, 2023 → Feb 1, 2029
NCT ID
NCT06111235About Cretostimogene Grenadenorepvec
Cretostimogene Grenadenorepvec is a phase 3 stage product being developed by CG Oncology for Non Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06111235. Target conditions include Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06443944 | Pre-clinical | Active |
| NCT06567743 | Phase 2 | Recruiting |
| NCT06111235 | Phase 3 | Active |
| NCT04452591 | Phase 3 | Active |
Competing Products
20 competing products in Non Muscle Invasive Bladder Cancer